



U.S. Trademark Electronic Search System (TESS)

TESS was last updated on Wed Dec 5 04:47:54 EST 2001

[PTO HOME](#) [TRADEMARK](#) [TESS HOME](#) [NEW USER](#) [STRUCTURED](#) [FREE FORM](#) [BROWSE DICT](#) [BOTTOM](#) [HELP](#)

[Logout](#) Please logout when you are done to release system resources allocated for you.

Record 1 out of 1

[Check Status](#) (TARR contains current status, correspondence address and attorney of record for this mark. Use the "Back" button of the Internet Browser to return to TESS)

Typed Drawing

Word Mark	PURICASE
Goods and Services	IC 005. US 006 018 044 046 051 052. G & S: pharmaceutical preparations containing uricase coupled to polyethylene glycol for use in the treatment of hyperuricemia and related conditions. FIRST USE: 19981217. FIRST USE IN COMMERCE: 19981217
Mark Drawing Code	(1) TYPED DRAWING
Serial Number	75324643
Filing Date	July 15, 1997
Filed ITU	FILED AS ITU
Published for Opposition	June 9, 1998
Registration Number	2246623
Registration Date	May 18, 1999
Owner	(REGISTRANT) MOUNTAIN VIEW PHARMACEUTICALS, INC. CORPORATION CALIFORNIA 3475-S Edison Way Menlo Park CALIFORNIA 940251813
Attorney of Record	ANNEMARIE KAISER
Type of Mark	TRADEMARK
Register	PRINCIPAL
Live/Dead Indicator	LIVE

[PTO HOME](#) [TRADEMARK](#) [TESS HOME](#) [NEW USER](#) [STRUCTURED](#) [FREE FORM](#) [BROWSE DICT](#) [TOP](#) [HELP](#)

AN 1998:2984 DRUGNL
TI PEG-uricase BioTechnology General, Duke University, Mountain View
licensing agreement
SO R&D Focus Drug News (24 Aug 1998).
WC 100
TX A licensing agreement has been signed by Mountain View and Duke
University
(USA) with BioTechnology General concerning a pegylated form of
recombinant uricase. BioTechnology General will develop the agent for the
treatment of gout. The enzyme uricase is produced by most mammals, but
not
by humans, and catalyses the break down of uric acid. The pegylated form
of the enzyme is expected to have a longer half life and increased
safety.
BioTechnology General intends to submit an application for Orphan Drug
status in the USA. The Israel-USA Binational Research and Development
Foundation will provide partial development funding for this project.

CN PEG-uricase; **PURICASE**
CC M4A Antigout Preparations
CO BioTechnology General
DSTA licensing agreement.
STA new drug

CN PEG-uricase; **PURICASE**
CC M4A Antigout Preparations
CO Mountain View
DSTA licensing agreement.
STA new drug

CN PEG-uricase; **PURICASE**
CC M4A Antigout Preparations
CO Duke University
DSTA licensing agreement.
STA new drug